Eli Lilly (NYSE:LLY) reported results showing its obesity treatment Zepbound significantly outperformed Novo Nordisk’s (CSE:NOVOb) weight loss drug Wegovy in the latest 72-week SURMOUNT-5 clinical trial. The findings, presented this weekend at the European Congress on Obesity, could shift dynamics in the rapidly expanding anti-obesity market.

Trial Overview and Results

• Weight Loss Statistics: Zepbound participants achieved an average weight reduction of 20.2%, compared to 13.7% for Wegovy, leading to a 47% relative improvement.

• High-Response Rate: 64.6% of Zepbound patients lost at least 15% of their body weight, versus 40.1% for Wegovy.

• Comparative Measures: Zepbound additionally showcased more substantial reductions in waist circumference.

• Safety Profile: Both medications exhibited primarily gastrointestinal side effects consistent with earlier studies.

Each treatment was administered at their maximum approved doses, targeting individuals diagnosed with obesity or overweight without diabetes.

Market Reaction

• Novo Nordisk Shares: Experienced a decline of 5.7% in trading on the Copenhagen Exchange.

• Eli Lilly Stock: Dropped 2.9%, influenced by President Trump’s intent to implement an executive order reducing prescription medicine prices.

Strategic Consequences for Eli Lilly

Zepbound’s superior effectiveness could fortify Eli Lilly’s competitive positioning in the obesity market, challenging Novo Nordisk’s dominance. As healthcare providers and payers evaluate clinical advantages, patient preferences are likely to shift.